Patient Assistance Applications: Matching Income Documents to the Program

Start with the Program, Not the Paperwork

A patient diagnosed with a complex chronic condition arrives at a clinic access desk or hospital hub seeking free medication through a manufacturer patient assistance program (PAP). The patient provides a standard envelope of financial paperwork: a prior-year Form W-2 showing $36,000, an annual Social Security disability award letter confirming $12,000, and a state unemployment determination letter establishing $9,000. Under traditional intake folklore, an access coordinator copies all three documents, attaches them to a generic application template, and faxes the bundle to the hub. In reality, whether this application succeeds, stalls in deficiency loops, or faces immediate administrative rejection depends almost entirely on which pharmaceutical manufacturer sponsors the product, how that specific program calculates countable earnings and who counts in the household, and what statutory Medicare conditions apply before financial criteria are even examined.

No public dataset reports how often income documents cause patient assistance denials, so this article does not estimate that share. What the program documents do show is that a complete-looking packet can still miss the rule that program actually applies. Access teams often treat manufacturer patient assistance programs as interchangeable charity pools with one paperwork standard. Each sponsor runs its own program, with its own income line, household wording, and Medicare screen. Manufacturer assistance to federal healthcare beneficiaries also has to be read against the anti-kickback statute and HHS Office of Inspector General guidance, which is why Part D files carry extra conditions. Commercial plans that steer high-cost drugs toward manufacturer free-product programs have pushed sponsors to add alternative-funding exclusions as well.

To cut avoidable deficiency loops, access navigators and specialty pharmacy hub teams can replace a generic paperwork stack with a five-step intake that starts from the program rules:

1. Product-to-Program Identification: Identify the exact National Drug Code (NDC) and trace the specific manufacturer foundation or corporate entity managing patient assistance for that medication. Never assume multi-product manufacturers share identical rules across different therapeutic categories.

2. Version-Controlled Form Retrieval: Download the active application directly from the manufacturer portal on the filing date. Confirm the internal form control number and publication date; major programs routinely reject outdated form versions without processing.

3. Definition-Specific Household and Income Computation: Calculate countable household income strictly according to the program's published instructions, accounting for specific exclusions (such as child support, food assistance, or alimony) or inclusions (gross pre-tax household wages, pensions, and public benefits).

4. Verification Mechanism Alignment: Assemble only the primary financial records that match the program's specific verification path, distinguishing between mandatory upfront tax forms, a consumer-report authorization, and credit-check consent.

5. Conditional Gate and Status Screening: Identify mandatory prerequisite filings dictated by payer status, such as Medicare Prescription Payment Plan election confirmations, Social Security Extra Help (Low-Income Subsidy) denial notices, or proof of commercial benefit exclusion.

flowchart TD
    A["Identify the product and open that program's current form"] --> B{"What coverage does this program accept?"}
    B -->|"Uninsured"| C["Apply this product's income ceiling"]
    B -->|"Medicare Part D"| D["Add only this program's Medicare documents"]
    B -->|"Commercial"| E{"Does this program accept the plan?"}
    E -->|"No, or the plan requires a PAP application"| H["Stop: commercial or alternative-funding exclusion"]
    E -->|"Yes, with published conditions"| C
    D --> D1["Pfizer: payment-plan proof; missing proof blocks processing above 138 percent FPL"]
    D --> D2["J&J: Extra Help evidence if Part D income is at or below 150 percent FPL"]
    D --> D3["Novo insulin: Extra Help denial below 150 percent FPL; Ozempic is closed to Part D"]
    D --> D4["Novartis: Extra Help denial as the page deems necessary"]
    D --> D5["Lilly: Medicaid, full LIS, and VA are exclusions"]
    D1 --> C
    D2 --> C
    D3 --> C
    D4 --> C
    D5 --> C
    C --> I["Count income with this program's inclusions and exclusions"]
    I --> J{"What the current form asks to attach"}
    J -->|"Pfizer"| K["W-2, paycheck stub, or prior-year tax return"]
    J -->|"Lilly"| L["Consumer-report consent; send documents only if requested"]
    J -->|"J&J"| M["1040 or 1040-SR is best practice, plus credit-check consent"]
    J -->|"Bausch"| P["Gross income excluding child support, food stamps, and alimony"]
    J -->|"PAN"| Q["Attested adjusted gross income; keep records for audit"]
    K --> N["File the current form version"]
    L --> N
    M --> N
    P --> N
    Q --> N

Where Each Program Sets Its 2026 Income Line

Many manufacturer assistance programs express financial limits as multiples of the federal poverty level (FPL). On January 15, 2026, the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE) published the annual poverty guidelines. For the 48 contiguous states and the District of Columbia, the 2026 baseline is $15,960 for a household of one, $21,640 for two, $27,320 for three, and $33,000 for four, adding $5,680 for each additional person. Alaska is $19,950 for one person and Hawaii is $18,360. Lilly, AbbVie, Sanofi, and Pfizer's updates page anchor published dollars to this guideline. That is not true of every sponsor. J&J's current form still prints 300% dollars from the prior guideline, Bausch does not publish a dollar cap, and Novo Nordisk states different FPL percentages by product. A new January guideline moves a ceiling only after that program adopts it.

Third-party summaries often describe a single 400% FPL ceiling. Primary pages do not. Pfizer RxPathways moved to 300% FPL for all products effective January 1, 2025, after a grace period for already enrolled patients between 301% and 500% FPL ended on December 31, 2024. Lilly Cares splits products into four medication groups at 300%, 400%, or 500% FPL. The table below compares the rules as checked on September 23, 2026. Dollar figures for Novo Nordisk are 2026 FPL arithmetic, because Novo publishes percentages rather than a dollar table. J&J's dollars are the amounts printed on the current enrollment form.

A secondary guide can send a team to the wrong ceiling. CareRoute's May 2026 guide still lists Pfizer RxPathways at up to 400% FPL, with some oncology drugs higher, Lilly Cares at up to 400% FPL, and myAbbVie Assist at up to 500% FPL. It also approximates a single-person 300% line at about $46,800 and a 400% line at about $62,400. Pfizer's own patient resources page still displays a separate 2021 block: eligibility 'starts at 400%,' $51,520 for one person and $106,000 for four. The controlling Pfizer updates page, checked September 23, 2026, sets 300% FPL for all products, $47,880 for one person in the 48 states. A household at 350% FPL is over that published ceiling. Read the current form or updates page before preparing the application.

Income and Household, Defined by the Program

Even when an access team knows a program's FPL percentage, calculating whether the patient qualifies requires applying that specific program's definitions of countable income and household size. The same family and paperwork stack will generate significantly different financial totals depending on which application instructions are followed.

Variations in Countable Income

Most manufacturer programs evaluate pre-tax gross annual household income, but they diverge widely on which financial inflows must be counted and which are excluded:

• Lilly Cares Foundation: The form asks for annual household income before taxes. The printed inclusions are wages, Social Security payments, disability and/or unemployment benefits, pensions, and any other income of the applicant and those in the household. If there is no household income, the instruction is to enter 0. During processing, Lilly may ask for documentation showing that income.

• Bausch + Lomb Patient Assistance: The eligibility screen asks for total annual household income for everyone in the household, gross before taxes and deductions, and says not to include child support, food stamps, or alimony. If the person was recently unemployed, it says to include current income and documentation. It does not say to discard a prior-year tax return or to replace another household member's W-2 with a termination letter.

• PAN Foundation: A current findhelp listing asks PAN applicants for adjusted gross annual household income, identification, insurance, diagnosis, and provider details. That wording is not Lilly's before-tax 'any other income' line, and the listing does not equate the figure to a specific line of Form 1040. The June 2022 PAN program review describes audits of sampled applications and re-verification before a renewal grant.

Variations in Household Definition

Household size serves as the denominator that determines which FPL poverty dollar line governs the case. Programs do not share one household rule, and some forms never define the term:

• No dependency test on the current form (Johnson & Johnson): The current enrollment form prints a Household/Family Size column and a 300% dollar table. The PDF text does not define household as people who live in the home and depend on that income, and it does not define household by who is claimed on a tax return. Do not copy Lilly's 'all family members' instruction onto a J&J file. If it is unclear who belongs in the household, call the program before filing.

• Family Relationship and Shared Domicile (Lilly Cares): The income table header counts the applicant and all family members. The income line asks for the listed income of the applicant and those in the household. The form does not say to omit a family member who files a separate tax return.

What to Attach: The Documents Each Program Actually Wants

A common working assumption is that every patient assistance application needs the same physical proof-of-income packet. The current forms do not say that. Pfizer asks for a W-2, paycheck stub, or prior-year tax return up front. Lilly may estimate income from a consumer report and request documents later. J&J lists a Form 1040 or 1040-SR as best practice and also authorizes a credit check. PAN attests first and audits a sample. Novartis asks for proof of income as deemed necessary.

Matching the request avoids two opposite mistakes: collecting a multi-year transcript for Lilly before Lilly has asked for it, and sending a Pfizer application with none of the three documents the patient page names. Pfizer does not publish a promise that a missing W-2 produces a specific queue status. It does say proof of income is required for the application to be evaluated.

Medicare Conditions That Change the Document List

Document mapping matters most for Medicare beneficiaries, because the extra papers are conditions of the program, not a second copy of the income packet. Uninsured applicants are screened on the program's own residency and income rules. Novo Nordisk asks for U.S. citizenship or legal residence. Lilly asks for permanent residence in the United States, Puerto Rico, or the U.S. Virgin Islands. Pfizer asks for residence in the United States or an applicable territory. None of those pages uses citizenship as a universal test, and none of them reviews the file as a clinical chart.

The OIG Anti-Kickback Boundary and Outside-the-Benefit Rules

In November 2005, the HHS Office of Inspector General published its landmark Special Advisory Bulletin on Patient Assistance Programs for Medicare Part D Enrollees. The OIG warned that pharmaceutical manufacturer subsidies of cost-sharing amounts for Part D drugs pose substantial risks under the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), because providing financial subsidies to induce the purchase of a manufacturer's federally reimbursable drug can skew prescribing decisions and increase federal healthcare spending.

CMS describes a lawful path in which manufacturer PAPs assist Part D enrollees by operating outside the Part D benefit, so the free product stays separate from the benefit. Assistance provided that way does not count toward a beneficiary's true out-of-pocket (TrOOP) costs. PAPs that want to exchange data files with CMS, so they can tell which beneficiaries are in Part D, complete a PAP attestation. The programs' Extra Help screens and 'do not count this product toward TrOOP' certifications sit on top of that outside-the-benefit model. They are not a rule that every Medicare beneficiary is ineligible for manufacturer assistance.

Pfizer RxPathways and the Medicare Prescription Payment Plan (M3P)

The Medicare Prescription Payment Plan is a voluntary option that spreads Part D out-of-pocket costs across monthly plan bills. It does not lower the total. CMS's September 2025 fact sheet states that the annual out-of-pocket maximum for covered Part D drugs is $2,100 in 2026, whether or not the person uses the payment plan. Pfizer's 2026 enrollment language tells applicants to attest that they know this $2,100 maximum. That $2,100 maximum is the 2026 amount.

Pfizer requires Medicare Part D and Medicare Advantage patients who want assistance with a covered Pfizer product to enroll in the Medicare Prescription Payment Plan before requesting PAP help, and to submit proof of that enrollment. A plan's Notice of Acceptance of Election is one document Pfizer names. If proof is missing, Pfizer says the enrollment form will not be processed for patients whose annual pre-tax household income is above 138% FPL. Patients also attest that they are enrolled, that they know the monthly copay and the $2,100 out-of-pocket maximum, that they cannot afford the copay, and that they have not yet reached the out-of-pocket maximum. Someone who does not enroll has not met that published precondition.

The 150% FPL Extra Help (LIS) Denial Screen

Extra Help, also called the Low-Income Subsidy, is the federal premium and cost-sharing subsidy for Part D. Manufacturer screens that say '150% of FPL' are applied to the household the program defines. Calculated from the January 15, 2026 guidelines for the 48 states, 150% is $23,940 for one person, $32,460 for two, $40,980 for three, and $49,500 for four. Those dollar figures are poverty-guideline arithmetic. They are not a quote from a Social Security four-person chart. Extra Help also has resource limits, and Alaska and Hawaii use higher guidelines. The document a program can act on is the denial or ineligibility notice, not this multiplication.

The 150% screen is not one rule shared by every sponsor. On the current J&J form, a person with Medicare prescription drug coverage and income equal to or less than 150% FPL must demonstrate that they are not eligible for Extra Help. On Novo Nordisk's Medicare insulin section, a beneficiary whose household income is below 150% FPL must provide proof of an Extra Help denial. Novo also says that someone eligible for Medicaid or Medicare Extra Help must submit the denial letter. Novartis requires proof of income and evidence of an Extra Help denial as deemed necessary. Its main page does not publish a 150% dollar trigger. Lilly takes the opposite structure for full Extra Help: people enrolled in full LIS are ineligible, rather than invited to file a denial and continue. A file at 120% FPL is incomplete at J&J and on Novo's insulin path until the Extra Help evidence is attached. That is a missing-document condition, not a finding that the lower income itself fails the PAP.

Categorical Exclusion Programs

In contrast to programs that review Part D enrollees under conditional screening, Lilly Cares Foundation enforces strict categorical exclusions. Under the CMAT-02998 program terms, patients actively enrolled in Medicaid, beneficiaries receiving full Low-Income Subsidy (LIS) support, and individuals covered by Veterans Health Administration (VA) pharmacy benefits are ineligible for Lilly Cares assistance across all medication groups.

A Worked Application Record

The opening example used three papers: a W-2, a disability award, and an unemployment letter. The record below adds a $6,000 child-support order so a published exclusion can be tested. Every dollar of patient income here is illustrative. The ceilings are the published 2026 guidelines, the dollars printed on the Lilly and J&J forms, or arithmetic labeled as calculated. None of the rows is an enrollment decision.

The 2026 HHS poverty baseline for a household of three in the 48 contiguous states is $27,320. Benchmarks for this household of three:

• 138% FPL (Pfizer M3P Gate Line): $37,702

• 150% of the 2026 three-person poverty guideline: $40,980

• 300% FPL (Pfizer & Lilly Group 1 Ceiling): $81,960

• 400% of the 2026 three-person guideline: $109,280

• 500% FPL (Lilly Groups 3 & 4 Ceiling): $136,600

• 200% of the 2026 three-person guideline (uninsured Ozempic): $54,640, calculated. Novo does not print this dollar.

• J&J printed cap, household of three, 48 states: $79,950 on the current form. That figure is 300% of the 2025 three-person guideline, not 300% of $27,320.

The table applies one illustrative stack to seven program rules. Counted income is $63,000 where the program does not publish a child-support exclusion. Lilly's 'any other income' line is the clearest inclusion. Bausch is the program that expressly says to leave child support out, so that row uses $57,000. 'Under the ceiling' means the illustrative income is at or below the published or printed line. It does not mean the program has approved the patient.

The Extra Help Inversion Trap

The same household can pick up a document requirement by having less income. Drop the spouse's $36,000 W-2 and the $6,000 child-support order. What remains is $21,000: $12,000 in SSDI and $9,000 in unemployment compensation. That figure is illustrative, and it assumes those two benefits are the only remaining income.

At $21,000, the household is at 76.9% of the three-person poverty guideline, under the $40,980 line that is 150% of that guideline. On the J&J form, Part D income at or below 150% FPL means the applicant must show they are not eligible for Extra Help before the free-product request proceeds. On Novo Nordisk's Medicare insulin section, income below 150% FPL means an Extra Help denial is required. Novartis may ask for that denial as deemed necessary; the page does not publish 150% as an automatic switch. The lower income does not, by itself, fail the PAP. It turns on a federal-subsidy document the higher-income version of this file did not need. If the product is Ozempic and the patient has Medicare drug coverage, Novo's page says the PAP is no longer available, at $21,000 or at $63,000. If the patient is uninsured and the product is Ozempic, $21,000 is under the calculated 200% line of $54,640, which the $63,000 stack was not.

When the Documents Do Not Fit the Form

In clinical access navigation, standard tax filings and steady pay stubs are often missing. Access coordinators routinely encounter non-standard income scenarios that require specific documentary adaptations:

Non-Filers and Informal Earnings

When a program asks for a tax return and the person did not file, do not add a non-filing transcript or a notarized affidavit the program has not named. Pfizer's patient page names a W-2, a paycheck stub, or the prior year's tax return. Lilly's form says to enter 0 when there is no household income, and it says documentation may be requested during processing. Use the document that program names.

Stale Tax Returns After Employment Disruption

A prior-year W-2 or tax return can describe a job the person no longer has. Pfizer still lists that prior-year return as acceptable proof of income, and it does not publish a rule that a termination letter replaces it. Bausch is the program that speaks to this fact pattern directly: if the person was recently unemployed, include current income and documentation. A 2025 return showing $75,000 does not, on Pfizer's published 2026 table, tell you the result until you know household size. For one person, $75,000 is over the $47,880 ceiling. For three people, the 300% ceiling is $81,960. Send the document the program asked for, and do not promise that a cover letter will reset the count.

Alternative Funding Programs (AFPs) and Exclusion Clauses

Some commercial plans send patients to a manufacturer free-product program as a condition of coverage. Lilly's form describes these arrangements as alternative funding programs, for-profit patient advocacy programs, or specialty cost-containment networks. J&J's form calls a related practice an Assistance Diversion Program: coverage or payment is withheld until the patient applies for free product. This article does not name vendors. The operational fact is the exclusion language on the form, not a directory of companies.

In response, manufacturers have updated their legal terms to explicitly disqualify AFP-directed applications:

• Lilly Cares Foundation: Explicitly bars any patient whose employer, health plan, or third-party plan administrator requires them to apply to Lilly Cares as a prerequisite for plan coverage or alternate benefit funding.

• myAbbVie Assist: Terms state that individuals enrolled in commercial plans that require applying to myAbbVie Assist as a condition of plan coverage are ineligible.

• Novartis Patient Assistance Foundation: Prohibits health plans, specialty pharmacies, pharmacy benefit managers (PBMs), and their third-party agents from submitting applications on behalf of patients, and explicitly denies assistance to individuals associated with alternative funding programs.

• Pfizer RxPathways 2026 Alternate Funding Requirement: Pfizer's 2026 updates page says that, before PAP consideration, patients must apply to all applicable, relevant, and available alternate funding resources, and that documentation of a denial may be required. The instruction is not limited to uninsured patients. A 2025 updates entry instead required written denial proof from diagnosis-specific independent charitable funds. Use the 2026 wording on the updates page, and keep the denial letter if the program asks for it.

Renewal, Re-Verification, and the January Reset

Securing initial patient assistance approval does not guarantee continuous therapy. Patient assistance is granted for finite authorization windows that follow distinct operational calendars:

• Rolling 12-Month vs Calendar-Year Expiration: Lilly's patient certification says that if the application is approved, enrollment generally expires in 12 months, or at the end of the calendar year for Medicare Part D, and the patient must reapply. That is Lilly's statement. It is not a calendar every manufacturer prints. J&J's terms say the program offer expires at the end of each calendar year and may change or end without notice.

• Novo Nordisk Fall Re-enrollment Window: NovoCare says patients may submit a new application 30 days before enrollment ends, and that Medicare Part D patients may apply after October 15 of the current year to enroll for the following year. The same page tells Part D patients they may apply for next year's enrollment after October 15, 2026. Filing in that window does not promise uninterrupted shipments.

• The Mid-January HHS Reset: When ASPE publishes new poverty guidelines, programs that adopt them move their dollar ceilings. Pfizer's updates page already shows the 2026 one-person 300% line at $47,880. J&J's current form still prints $46,950 for one person in the 48 states, which is $930 lower and matches 300% of the 2025 one-person guideline of $15,650. An individual at $47,200 is under Pfizer's published 2026 ceiling and over J&J's printed ceiling. An individual at $49,000 is over both. Re-screening after the January release helps only when that program has adopted the new dollars.

• Form Version Expiration: Manufacturers regularly retire application forms when corporate policies or product lists change. Lilly Cares explicitly rejects outdated form versions upon receipt. Do not reuse a saved PDF after the program posts a new version. Download the current packet from the program site.

• Post-Approval Charitable Audits: PAN's June 2022 program review says sampled applicants must provide verification of financial eligibility, and that income is re-verified before a renewal grant. Keep the income record the fund asked for. The review does not publish how often audits occur or what share of grants are denied.

Operational Checklist for Access and Hub Teams

Before transmitting an application, an access team can check the file against the form in hand. Completing the list does not promise that the program will approve it.

1. Form Revision Check: Download the application from the program site on the day of filing. Lilly Cares says outdated applications are not accepted. The Lilly file checked for this article is form CMAT-02998, version 12/2025.

2. Product List Verification: Confirm the product is still offered on that program. Pfizer's 2026 list says Xeljanz and Bosulif accept no new patients starting July 1, 2026. Novo Nordisk says Medicare beneficiaries with prescription drug coverage are no longer eligible for Ozempic through the PAP, and that uninsured Ozempic patients must be at or below 200% FPL.

3. Income Inflow Mapping: Cross-reference reported household earnings against the program's specific inclusions and exclusions. Deduct child support, alimony, or SNAP if applying to Bausch + Lomb; aggregate all household family earnings if applying to Lilly Cares.

4. Household Definition Check: Use the definition printed on the form being filed. Lilly counts the applicant and all family members. J&J's current form does not define household by who is claimed on a tax return, and it does not define household as people who live in the home and depend on that income. Do not borrow either rule from another program.

5. Medicare Document Attachment: If the patient has Medicare Part D: (a) for Pfizer, enroll in the Medicare Prescription Payment Plan and attach proof, because missing proof prevents processing when household income is above 138% FPL; (b) for J&J, if income is at or below 150% FPL, attach evidence the patient is not eligible for Extra Help; (c) for Novo Nordisk insulin, a Medicare beneficiary below 150% FPL needs an Extra Help denial, and anyone eligible for Medicaid or Extra Help needs the denial letter; (d) for Novartis, include Extra Help denial evidence as the foundation deems necessary. Novartis does not publish a 150% switch. Lilly excludes full LIS instead of asking for a denial letter.

6. Alternative Funding Program Disclosure: Confirm that the patient's commercial plan does not mandate PAP enrollment through an AFP vendor, avoiding categorical exclusion clauses.

7. Signatures and Consent: Ensure all required patient authorizations—especially consumer report soft-pull disclosures and HIPAA information release consents—are fully executed with handwritten or compliant digital signatures.

Limits of This Workflow

This operational analysis evaluates published policies, application instructions, and regulatory frameworks across eight major pharmaceutical manufacturer programs and one leading independent copay charity as of September 2026. Several methodological and structural limitations must be acknowledged:

• Sample Scope: This analysis covers high-volume specialty and chronic disease manufacturers; specialized rare-disease foundations, small biotech programs, and institution-specific charity funds operate separate proprietary guidelines.

• Unilateral Terms Modification: Pharmaceutical manufacturers retain unilateral legal discretion to modify income limits, alter formulary eligibility, introduce new documentation hurdles, or suspend programs entirely without advance public notice.

• Absence of Public Claims Data: No public clearinghouse publishes claims-level approval or denial statistics across manufacturer patient assistance programs. Consequently, denial rates cannot be quantified empirically from commercial claims registries.

• Professional Practice Notice: This analysis is authored for healthcare market access professionals, specialty pharmacy case managers, and hospital reimbursement teams. It does not constitute individualized medical, legal, or financial counseling. Access teams must verify controlling requirements on each program's primary portal prior to filing.

Sources

The analysis and data in this report are drawn from primary manufacturer application documents, corporate program policies, and federal regulatory notices:

• Lilly Cares Foundation Patient Assistance Program Application (form CMAT-02998, version 12/2025) — Eli Lilly and Company / Lilly Cares Foundation (Accessed September 23, 2026).

• myAbbVie Assist: Income criteria — AbbVie Inc. (Accessed September 23, 2026).

• Pfizer RxPathways: Program updates (2025 and 2026 eligibility requirements) — Pfizer Inc. (Accessed September 23, 2026).

• Pfizer RxPathways: Resources for patients (eligibility and enrollment requirements) — Pfizer Inc. (Accessed September 23, 2026).

• Patient Assistance Program enrollment form (Janssen CarePath / J&J withMe) — Johnson & Johnson Health Care Systems Inc. (Accessed September 23, 2026).

• Novo Nordisk Patient Assistance Program (NovoCare) — Novo Nordisk Inc. (Accessed September 23, 2026).

• Novartis Patient Assistance Foundation: eligibility and enrollment — Novartis Patient Assistance Foundation, Inc. (Accessed September 23, 2026).

• Bausch + Lomb Patient Assistance Program: eligibility screening — Bausch Health Companies Inc. / Bausch + Lomb (Accessed September 23, 2026).

• Sanofi Patient Connection: Financial eligibility for patient assistance — Sanofi US (Accessed September 23, 2026).

• HHS Poverty Guidelines (2026) — U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation (Published January 15, 2026; Accessed September 23, 2026).

• OIG Special Advisory Bulletin: Patient Assistance Programs for Medicare Part D Enrollees (November 2005) — Department of Health and Human Services, Office of Inspector General (Accessed September 23, 2026).

• Pharmaceutical Manufacturer Patient Assistance Program Information — Centers for Medicare & Medicaid Services (Accessed September 23, 2026).

• What's the Medicare Prescription Payment Plan? (CMS Product No. 12211, September 2025) — Centers for Medicare & Medicaid Services (Accessed September 23, 2026).

• PAN Foundation Program Review Report (June 2022) — Patient Access Network Foundation (Accessed September 23, 2026).

• PAN Foundation prescription copay grant assistance listing (findhelp) — findhelp (Accessed September 23, 2026).

• Patient Assistance Programs: Free or Low-Cost Medications (2026 Guide) — CareRoute (Accessed September 23, 2026). Used only as an example of a secondary threshold table that conflicts with current program pages.

• Patient Assistance Program Guide (2026): Eligibility and Steps — SIRUM (Accessed September 23, 2026).

• Market Access Trends Impacting Your Patient Assistance Program — Managed Markets Insight & Technology (MMIT) (Accessed September 23, 2026).